Literature DB >> 16472207

Amyloid beta: the alternate hypothesis.

Hyoung-gon Lee1, Xiongwei Zhu, Akihiko Nunomura, George Perry, Mark A Smith.   

Abstract

Alzheimer disease (AD) is a devastating condition and patients, caregivers, clinicians, and scientists are eager to decipher the underlying disease mechanism and, thereafter, target this therapeutically. Most investigators studying the underlying cause of AD have focused on amyloid-beta (Abeta) such that the Amyloid Cascade Hypothesis is the predominant mechanism thought to be responsible for the disease. However, a number of caveats have led us to seriously question the validity of this hypothesis. First, in addition to increases in Abeta, genetic mutations in AD lead to increased vulnerability to oxidative/apoptotic insults indicating that the mutated protein disturbs redox balance. Whether mutations result in Abeta deposition that then causes oxidative stress or whether mutations cause oxidative stress that results in Abeta deposition is unclear. Indeed, while in vitro experiments show that Abeta can directly cause oxidative stress to cells in culture, it is apparent from other studies that the reverse is also true, namely that oxidative stress leads to increases in Abeta. Notably, in vivo studies in both sporadic and genetic forms of the disease show that oxidative stress temporally precedes increases in Abeta and that increases in Abeta are associated with a decrease in oxidative stress. Based on these findings, we herein propose an Alternate Amyloid Hypothesis in which pathogenic factors for disease lead to increased oxidative stress that then leads to increases in Abeta. Further, we propose that Abeta serves as a redox sensor and that oxidatively-induced Abeta serves to attenuate oxidative stress. Obviously, whether Abeta is the culprit, as argued by the Amyloid Cascade Hypothesis, or a much maligned protector, as argued by the Alternate Amyloid Hypothesis, is clearly important to decipher to advance our understanding and design efficacious therapeutics for this disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16472207     DOI: 10.2174/156720506775697124

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  31 in total

Review 1.  Natural products as a source of Alzheimer's drug leads.

Authors:  Philip Williams; Analia Sorribas; Melanie-Jayne R Howes
Journal:  Nat Prod Rep       Date:  2010-11-12       Impact factor: 13.423

Review 2.  Amyloid-modifying therapies for Alzheimer's disease: therapeutic progress and its implications.

Authors:  Meaghan C Creed; Norton W Milgram
Journal:  Age (Dordr)       Date:  2010-04-20

3.  Amyloid-beta vaccination: testing the amyloid hypothesis?: heads we win, tails you lose!

Authors:  Hyoung-gon Lee; Xiongwei Zhu; Akihiko Nunomura; George Perry; Mark A Smith
Journal:  Am J Pathol       Date:  2006-09       Impact factor: 4.307

4.  Nanoparticle-chelator conjugates as inhibitors of amyloid-beta aggregation and neurotoxicity: a novel therapeutic approach for Alzheimer disease.

Authors:  Gang Liu; Ping Men; Wataru Kudo; George Perry; Mark A Smith
Journal:  Neurosci Lett       Date:  2009-03-25       Impact factor: 3.046

5.  Memantine: "hypothesis testing" not "disease modifying" in Alzheimer's disease.

Authors:  Massimo Tabaton; George Perry; Xiongwei Zhu; Hyoung-gon Lee; Gemma Casadesus; Mark A Smith
Journal:  Am J Pathol       Date:  2009-12-17       Impact factor: 4.307

Review 6.  Alzheimer's disease pathologic cascades: who comes first, what drives what.

Authors:  Russell H Swerdlow
Journal:  Neurotox Res       Date:  2011-09-13       Impact factor: 3.911

7.  Tumor necrosis factor-alpha-elicited stimulation of gamma-secretase is mediated by c-Jun N-terminal kinase-dependent phosphorylation of presenilin and nicastrin.

Authors:  Lan-Hsin Kuo; Ming-Kuan Hu; Wen-Ming Hsu; Ying-Tsen Tung; Bo-Jeng Wang; Wang-Wei Tsai; Chen-Tung Yen; Yung-Feng Liao
Journal:  Mol Biol Cell       Date:  2008-07-30       Impact factor: 4.138

Review 8.  Antioxidant therapy in Alzheimer's disease: theory and practice.

Authors:  Gjumrakch Aliev; Mark E Obrenovich; V Prakash Reddy; Justin C Shenk; Paula I Moreira; Akihiko Nunomura; Xiongwei Zhu; Mark A Smith; George Perry
Journal:  Mini Rev Med Chem       Date:  2008-11       Impact factor: 3.862

Review 9.  All-trans retinoic acid as a novel therapeutic strategy for Alzheimer's disease.

Authors:  Hyun-Pil Lee; Gemma Casadesus; Xiongwei Zhu; Hyoung-gon Lee; George Perry; Mark A Smith; Katarzyna Gustaw-Rothenberg; Alan Lerner
Journal:  Expert Rev Neurother       Date:  2009-11       Impact factor: 4.618

10.  S100A7, a novel Alzheimer's disease biomarker with non-amyloidogenic alpha-secretase activity acts via selective promotion of ADAM-10.

Authors:  Weiping Qin; Lap Ho; Jun Wang; Elaine Peskind; Giulio Maria Pasinetti
Journal:  PLoS One       Date:  2009-01-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.